NEUROCRINE BIOSCIENCES INC (NBIX) Operating Margin
- Operating margin · 12 months: Value 23.56%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 23.56% | Operating income / revenue. Period ending 2026-06-30. $794.80M ÷ $3.37B × 100 ≈ 23.56% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 794.80M USD | Operating Income (Loss) |
| Revenue | 3.37B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | 1.35B USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $794.80M | $3.37B | (m) | (m) | $1.35B | 23.56% |
| 2026-03-31 | $788.90M | $3.10B | $56.70M | (m) | $1.20B | 25.43% |
| 2025-12-31 | $619.10M | $2.86B | $52.10M | (m) | $1.16B | 21.64% |
| 2025-09-30 | $550.20M | $2.68B | $43.80M | (m) | $1.14B | 20.51% |
| 2025-06-30 | $495.00M | $2.51B | $37.80M | (m) | $1.08B | 19.72% |
| 2025-03-31 | $494.80M | $2.41B | $35.70M | (m) | $1.04B | 20.51% |
| 2024-12-31 | $570.50M | $2.36B | $34.00M | (m) | $1.01B | 24.22% |
| 2024-09-30 | $578.80M | $2.24B | $33.20M | (m) | $938.30M | 25.81% |
| 2024-06-30 | $536.20M | $2.12B | $36.40M | (m) | $908.20M | 25.30% |
| 2024-03-31 | $464.40M | $1.98B | $38.70M | (m) | $888.00M | 23.43% |
| 2023-12-31 | $250.90M | $1.89B | $39.70M | (m) | $887.60M | 13.30% |
| 2023-09-30 | $204.00M | $1.78B | $38.90M | (m) | $851.60M | 11.44% |
| 2023-06-30 | $150.60M | $1.67B | $33.80M | (m) | $833.70M | 9.00% |
| 2023-03-31 | $131.70M | $1.60B | $27.10M | (m) | $794.70M | 8.24% |
| 2022-12-31 | $249.00M | $1.49B | $23.20M | (m) | $752.70M | 16.73% |
| 2022-09-30 | $109.30M | $1.39B | (m) | (m) | $726.30M | 7.87% |
| 2022-06-30 | $66.00M | $1.30B | (m) | (m) | $694.60M | 5.09% |
| 2022-03-31 | $74.10M | $1.21B | (m) | (m) | $655.00M | 6.14% |
| 2021-12-31 | $102.50M | $1.13B | (m) | (m) | $583.30M | 9.04% |
| 2021-09-30 | $210.60M | $1.07B | (m) | (m) | $533.30M | 19.69% |
| 2021-06-30 | $121.80M | $1.03B | (m) | (m) | $491.20M | 11.80% |
| 2021-03-31 | $135.60M | $1.05B | (m) | (m) | $444.50M | 12.97% |
| 2020-12-31 | $163.00M | $1.05B | (m) | (m) | $433.30M | 15.58% |
| 2020-09-30 | $139.98M | $1.04B | (m) | (m) | $428.06M | 13.43% |
| 2020-06-30 | $274.38M | $1.01B | (m) | (m) | $400.06M | 27.28% |
| 2020-03-31 | $232.18M | $886.79M | (m) | (m) | $384.36M | 26.18% |
| 2019-12-31 | $72.28M | $788.09M | (m) | (m) | $354.06M | 9.17% |
| 2019-09-30 | $45.43M | $675.57M | (m) | (m) | $321.83M | 6.73% |
| 2019-06-30 | $9.66M | $605.23M | $5.82M | $173.93M | $297.74M | 1.60% |
| 2019-03-31 | $-26.66M | $518.56M | $5.07M | $149.23M | $277.83M | -5.14% |
| 2018-12-31 | $36.90M | $451.24M | $4.89M | $160.52M | $248.93M | 8.18% |
| 2018-09-30 | $26.86M | $414.26M | (m) | $147.03M | $236.26M | 6.48% |
| 2018-06-30 | $-33.46M | $323.28M | (m) | $134.01M | $219.73M | -10.35% |
| 2018-03-31 | $-88.88M | $232.71M | (m) | $118.89M | $200.49M | -38.19% |
| 2017-12-31 | $-131.36M | $161.63M | (m) | $121.83M | $169.91M | -81.27% |
| 2017-09-30 | $-189.45M | $67.11M | (m) | $118.80M | (m) | -282.30% |
| 2017-06-30 | $-221.89M | $6.33M | (m) | $117.28M | (m) | -3502.56% |
| 2017-03-31 | $-206.45M | $0.00 | (m) | $122.27M | (m) | (m) |
| 2016-12-31 | $-147.37M | $15.00M | (m) | $94.29M | (m) | -982.48% |
| 2016-09-30 | $-131.87M | $15.00M | (m) | $93.52M | (m) | -879.13% |
| 2016-06-30 | $-129.28M | $15.00M | (m) | $96.96M | (m) | -861.85% |
| 2016-03-31 | $-112.77M | $15.00M | (m) | $88.82M | (m) | -751.81% |
| 2015-12-31 | $-94.20M | $19.77M | (m) | $81.49M | (m) | -476.51% |
| 2015-09-30 | $-83.92M | $19.77M | (m) | $75.18M | (m) | -424.51% |
| 2015-06-30 | $-64.94M | $19.77M | (m) | $62.99M | (m) | -328.47% |
| 2015-03-31 | $-53.97M | $19.77M | (m) | $54.43M | (m) | -273.02% |
| 2014-12-31 | $-64.41M | $0.00 | (m) | $46.42M | (m) | (m) |
| 2014-09-30 | $-55.47M | $730.00K | (m) | $39.84M | (m) | -7599.04% |
| 2014-06-30 | $-50.62M | $1.46M | (m) | $37.14M | (m) | -3469.64% |
| 2014-03-31 | $-49.43M | $2.19M | (m) | $37.51M | (m) | -2258.02% |
| 2013-12-31 | $-49.68M | $2.92M | (m) | $39.25M | (m) | -1701.88% |
| 2013-09-30 | $-29.57M | $24.14M | (m) | $39.43M | (m) | -122.50% |
| 2013-06-30 | $-21.52M | $32.76M | (m) | $39.80M | (m) | -65.69% |
| 2013-03-31 | $-9.73M | $42.60M | (m) | $38.09M | (m) | -22.85% |
| 2012-12-31 | $1.45M | $53.14M | (m) | $37.16M | (m) | 2.72% |
| 2012-09-30 | $-6.69M | $42.30M | (m) | $36.07M | (m) | -15.81% |
| 2012-06-30 | $27.71M | $74.58M | (m) | $33.66M | (m) | 37.16% |
| 2012-03-31 | $30.19M | $76.17M | (m) | $33.02M | (m) | 39.64% |
| 2011-12-31 | $33.92M | $77.41M | (m) | $30.95M | (m) | 43.82% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-13.72M | $33.50M | (m) | $31.15M | (m) | -40.96% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-53.67M | $2.95M | (m) | $33.72M | (m) | -1817.47% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |